Ilyang Pharmaceutical Co.,Ltd (007575) - Total Liabilities

Latest as of June 2026: ₩194.78 Billion KRW ≈ $132.00 Million USD

Based on the latest financial reports, Ilyang Pharmaceutical Co.,Ltd (007575) has total liabilities worth ₩194.78 Billion KRW (≈ $132.00 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ilyang Pharmaceutical Co.,Ltd (007575) long-term investment share to see how much of total assets are deployed in long-term investments.

Ilyang Pharmaceutical Co.,Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Ilyang Pharmaceutical Co.,Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 007575 current and non-current assets.

Ilyang Pharmaceutical Co.,Ltd Competitors by Total Liabilities

The table below lists competitors of Ilyang Pharmaceutical Co.,Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
FG Merger II Corp. Unit NASDAQ:FGMCU	USA	$194.92K
Freeman Gold Corp V:FMAN	Canada	CA$1.40 Million
Ubiquoss Holdings Inc KQ:078070	Korea	₩34.48 Billion
ITEK Inc KQ:119830	Korea	₩47.77 Billion
JAKS Resources Bhd KLSE:4723	Malaysia	RM837.51 Million
Western Asset Investment Grade Defined Opportunity Closed Fund NYSE:IGI	USA	$2.75 Million
Cardiff Oncology Inc NASDAQ:CRDF	USA	$16.50 Million
Maronan Metals Ltd AU:MMA	Australia	AU$700.14K

Liability Composition Analysis (2014–2025)

This chart breaks down Ilyang Pharmaceutical Co.,Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Ilyang Pharmaceutical Co.,Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.88	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.77	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.43	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ilyang Pharmaceutical Co.,Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ilyang Pharmaceutical Co.,Ltd (2014–2025)

The table below shows the annual total liabilities of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩215.92 Billion ≈ $146.33 Million	+12.76%
2024-12-31	₩191.49 Billion ≈ $129.77 Million	+19.49%
2023-12-31	₩160.25 Billion ≈ $108.60 Million	-22.33%
2022-12-31	₩206.33 Billion ≈ $139.83 Million	-7.27%
2021-12-31	₩222.51 Billion ≈ $150.79 Million	+14.58%
2020-12-31	₩194.19 Billion ≈ $131.60 Million	-9.56%
2019-12-31	₩214.72 Billion ≈ $145.51 Million	-3.44%
2018-12-31	₩222.37 Billion ≈ $150.70 Million	-1.34%
2017-12-31	₩225.39 Billion ≈ $152.74 Million	+5.37%
2016-12-31	₩213.91 Billion ≈ $144.96 Million	-3.04%
2015-12-31	₩220.62 Billion ≈ $149.51 Million	-10.81%
2014-12-31	₩247.37 Billion ≈ $167.64 Million	--

About Ilyang Pharmaceutical Co.,Ltd

KO:007575 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$92.33 Million

₩136.24 Billion KRW

Market Cap Rank

#19573 Global

#993 in Korea

Share Price

₩7500.00

Change (1 day)

+0.94%

52-Week Range

₩7000.00 - ₩12980.00

All Time High

₩141909.13